Archive for September 2013

U.S. News and World Report Recognizes Temple University Hospitals

September 25, 2013

A graduate of the Temple University School of Medicine, Lindsay Rosenwald remains active in his alma mater by serving on its board of visitors. Today, Lindsay Rosenwald focuses his professional energy within the biotechnology investment sector and co-heads an asset management firm.

This summer, U.S. News and World Report released its list of the country’s best hospitals for 2013-2014. As in previous years, Temple University Hospital earned a place on the organization’s regional list; furthermore, it received recognition for excellence in eight specialties, including neurology, pulmonology, and gynecology.

Additionally, the university-affiliated Fox Chase Cancer Center was named among the nation’s top hospitals for cancer care. One of the country’s first cancer hospitals, the Fox Chase Cancer Center has offered compassionate care to patients for nearly 100 years. In addition to its designation as one of the country’s top 30 cancer hospitals, the center was ranked 11th among all hospitals in Pennsylvania.

For more information about the Temple University School of Medicine and its recent awards, please visit www.temple.edu.

Advertisements

FDA Recognizes Need for Patient-Centric Drug Development

September 20, 2013

Over the last two decades, Dr. Lindsay Rosenwald has founded and invested in an array of biotechnology start-ups, funding research and development for drugs to treat leukemia and prostate cancer. Today, Dr. Lindsay Rosenwald serves as a founding partner at an investment partnership in New York City.

Recently, the New England Journal of Medicine published an article discussing the need for more patient-centered drug development, specifically surrounding cancer treatment therapies. Physicians report that patients often ask how medications will make them feel, yet clinical trial data rarely includes patient accounts of how the drug affected their everyday lives. Thanks to advanced drugs and therapies, patients are often able to live longer with a disease; these advances only increase the importance of reporting on how a certain drug affects the patient’s quality of life.

Additionally, the U.S. Food and Drug Administration has recognized that drug developers often focus on a drug’s end result without taking the patient’s perspective into consideration. The agency has started taking steps to alleviate this challenge, but the aforementioned article recommends that the FDA raise its standards even higher. The New England Journal of Medicine’s commentator suggests identifying patient-centered outcomes and metrics during the earliest stages of drug development and using them to analyze patient feedback throughout pivotal trials. He believes that adopting this process could help improve quality of life for thousands of cancer patients.